Component: (Network and Table)
Network
00100 - Statement - Condensed Consolidated Balance Sheets
(http://www.immunomedics.com/role/StatementCondensedConsolidatedBalanceSheets)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Condensed Consolidated Balance Sheets [Abstract]Period [Axis]
2016-06-30
2015-06-30
Condensed Consolidated Balance Sheets [Abstract]
 
 
ASSETS
 
 
Current Assets:
 
 
Cash and cash equivalents
13,203,625  
13,452,775  
Marketable securities
37,424,221  
86,165,532  
Accounts receivable, net of allowance for doubtful accounts of $74,546 and $54,177 at June 30, 2016 and 2015, respectively
513,992  
345,627  
Inventory
350,524  
584,424  
Other receivables
236,768  
857,068  
Prepaid expenses
1,038,155  
1,136,103  
Other current assets
183,820  
945,673  
Total current assets
52,951,105  
 
103,487,202  
 
Property and equipment, net
3,969,163  
2,241,838  
Value of life insurance policies
 
20,566  
Other long-term assets
30,000  
30,000  
Total Assets
56,950,268  
 
105,779,606  
 
LIABILITIES AND STOCKHOLDERS' DEFICIT
 
 
Current Liabilities:
 
 
Accounts payable and accrued expenses
15,188,189  
11,808,223  
Deferred revenues
235,372  
271,667  
Total current liabilities
15,423,561  
 
12,079,890  
 
Convertible senior notes – net of unamortized debt issuance costs of $2,645,602 and $3,375,423 at June 30, 2016 and 2015, respectively
97,354,398  
96,624,577  
Other liabilities
1,699,276  
1,599,760  
Commitments and Contingencies (Note 13)
xsi:nil  
xsi:nil  
Stockholders' Deficit:
 
 
Preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at June 30, 2016 and at June 30, 2015
xsi:nil  
xsi:nil  
Common stock, $.01 par value; authorized 155,000,000 shares; issued 95,867,298 shares and outstanding 95,832,573 shares at June 30, 2016; issued 94,546,578 shares and outstanding 94,511,853 shares at June 30, 2015
958,672  
945,465  
Capital contributed in excess of par
311,320,651  
305,229,354  
Treasury stock, at cost, 34,725 shares at June 30, 2016 and at June 30, 2015
(458,370) 
(458,370) 
Accumulated deficit
(368,504,954) 
(309,468,004) 
Accumulated other comprehensive loss
(132,226) 
(161,092) 
Total Immunomedics, Inc. stockholders' deficit
(56,816,227) 
 
(3,912,647) 
 
Noncontrolling interest in subsidiary
(710,740) 
(611,974) 
Total stockholders’ deficit
(57,526,967) 
 
(4,524,621) 
 
Total Liabilities and Stockholders' Deficit
56,950,268  
 
105,779,606